COTA and GTC Partner to Improve Precision Oncology

What You Should Know:

– COTA, Inc., an oncology real-world data and analytics company, today announced a new partnership with Genomic Testing Cooperative (GTC), a molecular testing company.

– GTC has a very innovative approach to genetic testing, providing molecular information which is critical to determining accurate diagnoses and determining the most appropriate treatment. GTC’s tissue and liquid-biopsy testing leverages DNA and RNA sequencing, which is very rare in the industry, so together with COTA’s RWD platform (which had some biomarker data), care teams and researchers will have access to the industry’s most comprehensive suite of actionable oncology data.

What You Should Know:

– COTA, Inc., an oncology real-world data and analytics company, today announced a new partnership with Genomic Testing Cooperative (GTC), a molecular testing company.

– GTC has a very innovative approach to genetic testing, providing molecular information which is critical to determining accurate diagnoses and determining the most appropriate treatment. GTC’s tissue and liquid-biopsy testing leverages DNA and RNA sequencing, which is very rare in the industry, so together with COTA’s RWD platform (which had some biomarker data), care teams and researchers will have access to the industry’s most comprehensive suite of actionable oncology data.